The medical device industry’s compliance with the Foreign Corrupt Practices Act in the US will come under close scrutiny from the Department of Justice in the months and years ahead, the head of the department’s Criminal Division has warned1. While his remarks were addressed to the pharmaceutical industry, assistant attorney general Lanny Breuer made it clear that they also apply to the medical device industry...
Scrip Regulatory Affairs
Devices industry under scrutiny by US Justice Department
19 November 2009
Moira Dower
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- Pharma paid $2.2 bn in 2011 for false claims in US
- US HHS misses implementation deadline for transparency provision; drug, device firms concerned
- UK Bribery Act enters into force; companies urged to implement anti-corruption programmes
- UK Bribery Act enters into force; companies urged to implement anti-corruption programmes
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
